Bristol-Myers Shares Slide as Cancer-Drug Race Intensifies
This article is for subscribers only.
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo didn’t sell as well as analysts had expected in the fourth quarter, suggesting that the drugmaker is facing increasing pressure in a competitive market for immunotherapy treatments.